ArticleTherapeutic advances in medical oncology2013
The changing landscape in the treatment of metastatic castration-resistant prostate cancer.
Article in Therapeutic advances in medical oncology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 1 synthesis or guideline pooled it, 43 citations in OpenAlex.
- Health Economics and Radium-223 (Xofigo®) in the Treatment of Metastatic Castration-Resistant Prostate Cancer (mCRPC): A Case History and a Systematic Review of the Literature.Global journal of health science · 2015Pooled it
- The synergistic efficacy of lupeol and enzalutamide potentiates anticancer activity, inducing apoptosis and cell cycle arrest in breast cancer cells.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- P2Y1 agonist HIC in combination with androgen receptor inhibitor abiraterone acetate impairs cell growth of prostate cancer.Apoptosis : an international journal on programmed cell death · 2022Article
- Systematically understanding the immunity leading to CRPC progression.PLoS computational biology · 2019Article
- Ra-223 Treatment for Bone Metastases in Castrate-Resistant Prostate Cancer: Practical Management Issues for Patient Selection.American journal of clinical oncology · 2019Review
- Docetaxel and Doxorubicin Codelivery by Nanocarriers for Synergistic Treatment of Prostate Cancer.Frontiers in pharmacology · 2019Article
- Mechanisms and Approaches for Overcoming Enzalutamide Resistance in Prostate Cancer.Frontiers in oncology · 2018Review
- Imaging and treatment recommendations in patients with castrate-resistant prostate cancer.Reviews in urology · 2017Article
- Radioimmunotherapy of prostate cancer targeting human kallikrein-related peptidase 2.EJNMMI research · 2016Article
- Lentiviral vector-mediated insertional mutagenesis screen identifies genes that influence androgen independent prostate cancer progression and predict clinical outcome.Molecular carcinogenesis · 2016Article
- Targeting Bone Metastases in Metastatic Castration-Resistant Prostate Cancer.Clinical Medicine Insights. Oncology · 2016Review
- A combination of sorafenib and nilotinib reduces the growth of castrate-resistant prostate cancer.International journal of nanomedicine · 2016Article
- Comparative analysis of the effectiveness of abiraterone before and after docetaxel in patients with metastatic castration-resistant prostate cancer.World journal of clinical oncology · 2015Article
- Disease Progression/Clinical Outcome Model for Castration-Resistant Prostate Cancer in Patients Treated With Eribulin.CPT: pharmacometrics & systems pharmacology · 2015Article
- Prognostic Utility of PET in Prostate Cancer.PET clinics · 2015Review
- CSF1 receptor targeting in prostate cancer reverses macrophage-mediated resistance to androgen blockade therapy.Cancer research · 2015Article
- Synergistic simvastatin and metformin combination chemotherapy for osseous metastatic castration-resistant prostate cancer.Molecular cancer therapeutics · 2014Article
- Review
- Piperlongumine inhibits NF-κB activity and attenuates aggressive growth characteristics of prostate cancer cells.The Prostate · 2014Article
- From bench to bedside: the realities of reducing global prostate cancer disparity in black men.Ecancermedicalscience · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The past few years have brought increasing advances in the therapeutic management of metastatic castration-resistant prostate cancer with the approval of several agents, including vaccine therapy with sipuleucel-T, second-line chemotherapy with cabazitaxel, the bone-targeted pharmaceutical denosumab, and the novel antiandrogen therapy abiraterone acetate. There are ongoing developments with other agents in the pipeline such as MDV3100 and alpharadin that have shown promising results. This review describes the clinical trials that brought about the drug approvals of various agents and offers some insights regarding a rational approach to optimal treatment sequencing for these drugs since national guidelines are currently lacking.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.